Key Clinical Message
The novel time-limited combinations with the bcl-2 inhibitor Venetoclax
can induce deep responses even in CLL cases with unusual and
biologically aggressive presentations, like the skin masses of our
patient.
Keywords: CLL/SLL, Venetoclax, time-limited therapy, skin
nodules, MRD negativity